The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Therapeutic options for patients with primary refractory/early relapsed DLBCL
Manali Kamdar, MD, University of Colorado, Aurora, CO, gives an overview of treatment options available for patients with primary refractory and early relapsed diffuse large B-cell lymphoma (DLBCL), highlighting promising findings obtained from clinical trials. Dr Kamdar first discusses the need to look beyond autologous stem cell transplantation (autoSCT) in these patients, and further notes the value of CAR-T therapy and moving these agents into earlier lines. Following this, Dr Kamdar discusses findings from several pivotal trials, including ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), and PILOT (NCT03483103), and concludes by highlighting treatment options for patients ineligible for CAR-T therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
